Posted by Michael Wonder on 28 Sep 2021
European Medicines Agency grants Atara Biotherapeutics accelerated assessment of tab-cel for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease
27 September 2021 - Atara on track to submit MAA in November 2021.
Atara Biotherapeutics today announced the CHMP of the EMA has granted accelerated assessment to the Company’s lead product candidate, tabelecleucel (tab-cel), for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.
